PHARMACYCLICS, INC.

  • Is There Pipeline Potential in These 3 Biotech Stocks?

    By Sherrie Stone - August 7, 2013 | Tickers: PCYC, REGN, SRPT

    It is not uncommon for a biotechnology company to be valued solely on the potential of one drug. For many small and midcap biotechs, the potential of lead drugs has already led to large stock gains. Therefore, let’s look further down the pipeline at the market’s most exciting biotechs, and determine whether future upside exists.

    Treating The Disease, Not The Symptoms

    Regeneron Pharmaceuticals (NASDAQ: REGN) has rallied 700 more »

  • Pharmacyclics Set to Glide Higher

    By Terry Chrisomalis - July 31, 2013 | Tickers: BIIB, JNJ, PCYC

    Pharmacyclics (NASDAQ: PCYC) has been a good company to invest in, especially if you had bought shares back in 2009 when it traded around $1 per share. That's not to say it is too late, because this biotech company still has a lot of room to run higher. The reason for the continued run up will be the pipeline that continues to produce results. All of the candidates in more »

  • What Creates a Good Biotechnology Partnership?

    By Sherrie Stone - July 30, 2013 | Tickers: ARNA, PCYC, THRX

    It’s hard enough to successfully invest in biotechnology. Adding the prospects of a partnership and the value it creates can make the investment that much more complicated. In the space, there are good, bad, and fair partnerships, and knowing how to spot each will help you to make better investment decisions.

    Peak Sales Can Be Misleading

    Theravance (NASDAQ: THRX) investors have had a great first half to 2013, with more »

  • A Developing "Breakthrough" In Biotechnology that You Should Monitor

    By Sherrie Stone - July 12, 2013 | Tickers: ABBV, JNJ, PCYC

    For many years, biopharmaceutical companies, physicians, patients, and investors alike, have been seeking a quicker regulatory path for drugs that demonstrate superior clinical evidence and treat life-threatening diseases. In 2012, the FDA showed signs of progress, with the creation of the “Breakthrough Therapy” designation. Now, it’s crunch time, as the FDA must prove that this designation actually means something to patients, physicians, companies, and Wall Street.

    A “Breakthrough” Submission more »

  • Ahead of an FDA Decision, Do You Buy This Stock?

    By Sherrie Stone - July 12, 2013 | Tickers: ALXN, DNDN, PCYC

    Pharmacyclics (NASDAQ: PCYC) crossed $100 a share on Thursday, giving it a market cap of $7.4 billion and a one-year return of 73%. As the company prepares to seek FDA approval for its oncology drug candidate ibrutinib, has its valuation become too large to justify your investment?

    Promising Yet Expensive

    Pharmacyclics is at a crucial point in its history: It is seeking an FDA approval to treat mantle cell more »

  • Will This Biotech Acquisition Buzz Lead to More Buyouts?

    By Sherrie Stone - July 8, 2013 | Tickers: ARIA, ONXX, PCYC

    Onyx Pharmaceuticals (NASDAQ: ONXX) is trading higher after rejecting a takeover bid. As other stocks in its sector also trade higher in sympathy, will any of them become takeover targets, too?

    What’s Creating The Buzz

    The analysts, bloggers, and columnists were out in full force last Monday morning to assess the true “worth” of Onyx. The company markets cancer drugs Nexavar and Stivarga with Bayer, and solely develops Kyprolis more »

  • Amgen Stirs the Pot in the Cancer-Related Sector

    By Phillip Woolgar - July 6, 2013 | Tickers: AMGN, ONXX, PCYC

    Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where firms are looking to take any competitive advantage. The company that does manage to make the breakthrough that millions are waiting for will not only change the world, but also make a lot of shareholders very rich. 

    Amgen (NASDAQ: AMGN) in its more »

  • Look Before You Leap With This Company

    By Naomi Warmate-Igwe - July 2, 2013 | Tickers: ACAD, PCYC, SGEN

    ACADIA Pharmaceuticals (NASDAQ: ACAD) is a bio-pharmaceutical company that specializes in the innovation of small-molecule drugs that are used to treat complex neurological and Central Nervous System (CNS) disorders. The biotech firm is responsible for wonder drugs such as Pimavanserin, a drug that ACADIA is developing for the treatment of Parkinson’s disease Psychosis.

    ACADIA Pharmaceuticals’ stock has been massively bullish in the last one year, with current share price more »

  • 4 Stocks On The Verge Of Breaking Out!

    By Brian Nichols - June 4, 2013 | Tickers: ALU, AAPL, PCYC, RAD

    Rite Aid (NYSE: RAD) has been my favorite stock for the better part of the last year. I first began covering the stock when it was at $1.00 back in December 2012, and then quickly purchased a large position of the company after it reported Q3 earnings, at $1.23.

    Rite Aid had gone six years without posting a profit, and then all of a sudden posted two phenomenal more »

  • Three Value-Presenting Stocks With Upgrades on Monday

    By Brian Nichols - May 15, 2013 | Tickers: DDD, GLW, PCYC

    An analyst upgrade can sometimes be highly useful in allowing you to learn about a new company that might have flown under-the-radar. With the markets trading at all-time highs investors are scrambling to find the best opportunities. In this article I am looking at three stocks that I believe are presenting such an opportunity, even after upgrades on Monday.

    This Stock Continues to Rebound

    After a year of no return more »

  • Climbing the Wall of Worry

    By Declan Fallon - May 9, 2013 | Tickers: GWR, PCYC, SRE, XLU

    According to the American Association of Individual Investors (AAII), bullish sentiment clawed its way to 31%. What's unusual about the low level of optimism is how the S&P has been pushing new multi-year highs. Market rallies often have to climb a wall of worry, and it would appear there is plenty of "worry" left in the tank for this market to rise. It's only when everybody is more »

  • Right Time To Buy This Pharmaceutical Company?

    By Mike Thiessen - May 7, 2013 | Tickers: CYTR, PCYC, SGEN

    Pharmacyclics (NASDAQ: PCYC) reported 1Q13 earnings on May 1, and the shares sold off 5.5% over the course of the day. The company fell short of analyst earnings and revenue forecasts. However, this could be a buying opportunity for investors, since most of the stock’s value is in future cash flows from a leukemia and non-Hodgkin lymphoma treatment that actually progressed faster than expected in the quarter.

    Pharamcyclics more »

  • Tracking Cash Inflows: A Good Method to Locate Investment Opportunities

    By Jeff Stouffer - April 28, 2013 | Tickers: ALK, IWM, OCN, PCYC, TWO

    Exchange-traded funds have gained popularity for a variety of reasons. One feature that may assist the average investor in seeking investment opportunities is the daily transparency of the holdings. Observing the passive index following style empowers the investor to get a sense of what the exchange-traded fund will buy. These two elements may help uncover what stocks are being purchased by these funds.

    An investor may also choose to acquire more »

  • Mega-Hedge Fund Focusing on the Life Sciences

    By Meena Krishnamsetty - April 18, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

    The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

    Why should you watch hedge funds?

    Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time their picks routinely outperform. Let’s look at the top five picks more »

  • Mega-Hedge Fund Focusing on The Life Sciences

    By Meena Krishnamsetty - April 16, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

    The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

    Why should you watch hedge funds?

    Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time, their picks routinely outperform. For more than a decade in our back more »

  • Under-the-Radar Hedge Fund Focusing on Pharma

    By Meena Krishnamsetty - March 20, 2013 | Tickers: ARIA, PODD, PCYC, YMI.DL

    Hedge funds are typically thought of as being billion dollar funds managed by Harvard MBAs and alums of some of Wall Street’s more prestigious analyst programs (i.e. Goldman Sachs, JP Morgan). Interestingly, Dafna Capital Management is rather small (only $63 million) and is managed by Dr. Nathan Fischel MD and his wife, a biomedical engineer. So why are we even talking about Dafna? Because according to the most more »

  • A Pharmaceutical Growth Story You Can't Afford To Miss

    By Jordo Bivona - February 19, 2013 | Tickers: ABBV, GILD, GSK, MRK, PCYC

    Gilead Sciences (NASDAQ: GILD) is the world’s largest maker of HIV drugs, but has taken on a number of new initiatives to enter other areas of treatment. Gilead's stock rose almost 80% in 2012, the best increase in 17 years, primarily on the prospects of  its experimental hepatitis C drug, acquired in its $10.8 billion acquisition of Pharmasset. Gilead’s string of deals clearly indicates that the more »

  • The Market Hits Stall Speed as the market Digests the State of the Union

    By Joshua Hayes - February 13, 2013 | Tickers: AAPL, BWLD, CSCO, CMCSA, INVN, KORS, PCYC, PRLB, RAX

    Stocks enjoyed buying through the early morning session as Europe rebounded from its recent pullback. By 10:30 the market changed behavior as it simply could not maintain its high of the day. Thirty minutes prior to the European close the market took a nose dive and hit the lows of the session. Volume was running higher throughout the session and indicating the market had begun hitting stall speed. A more »

  • NASDAQ Stalls as Volume Finishes Higher

    By Joshua Hayes - February 13, 2013 | Tickers: AAPL, BWLD, INVN, KORS, NTGR, PCYC, RAX

    NASDAQ Composite continues to lag behind the Dow Jones Industrial Average and the S&P 500. Volume rose across the board, but remained below average. The NASDAQ notched a stall day and although it failed to register a day of distribution. Stalling days are nothing new and all it will take is for the NASDAQ to eclipse today’s high. Two star industries on the day were XLF and XHB more »

  • Baker Brothers Reports Stakes in InterMune and Repros Therapeutics

    By Meena Krishnamsetty - February 5, 2013 | Tickers: ITMN, PCYC, RPRX, SGEN, GEVA

    Baker Brothers, a healthcare focused hedge fund managed by Julian and Felix Baker, has recently filed with the SEC to disclose significant percentage stakes in two development stage biotechnology companies. The fund now owns 2.6 million shares of InterMune (NASDAQ: ITMN), giving it 3.3% of the outstanding shares of the stock, and 1.5 million shares, nearly 9%, of Repros Therapeutics (NASDAQ: RPRX).

    InterMune’s focus is on more »

  • Page 1 of 2